Although there were several encouraging preclinical data on the use of immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4 antibodies, alone or in combination) for glioblastoma, clinical trials have been disappointing, with no patient survival improvement [41,85]. The gene discussed is PDCD1; the disease is glioblastoma.